|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Accumetrics introduced its VerifyNow P2Y12 to test for Plavix response. The blood test is designed to measure the effects of Plavix on platelets, the blood cells primarily responsible for clotting. Plavix (clopidogrel) is taken by almost 10 million Americans to help prevent heart attack or stroke. Chemicon International, Inc., launched the Amplifluor ID Pan-Enterovirus Detection Reagent to detect Pan-Enterovirus. Chemicon currently has several other Amplifluor viral detection targets in development: Hepatitis B, Parvovirus B19, Babesia, Erhlichia, Lyme Disease, Influenza A & B, Herpes Simplex Viruses 1 & 2, and West Nile. CombiMatrix Group received a one year ($338,000) contract from the U.S. Air Force for the development and production of microarrays to detect pathogens that cause upper respiratory infections and pathogens that infect wounds. This contract is for the development of a rapid assay and microarray that identifies all serotypes of influenza A, including bird flu. The first array to be developed under the new contract will identify a number of upper respiratory infections that can cause potentially life threatening diseases (viral and bacterial pneumonia) or lead to pandemic infections (bird flu and SARS). Genzyme Corp. launched its EGFR Mutation Assay to identify patients likely to respond to therapies targeted for the treatment of non-small cell lung cancer (NSCLC). EGFR mutations have been shown to correlate with clinical response to certain drugs, including Tarceva (erlotinib) and IRESSA (gefitinib), used in treating this cancer. The test is offered by Genzyme's laboratory. STMicroelectronics and Mobidiag introduced the In-Check platform, a lab-on-chip application for DNA-based detection of sepsis-causing bacteria, using a diagnostic panel developed by Mobidiag to identify ten sepsis-causing bacterial species as well as methicillin-resistant strains of Staphylococcus aureus from positive blood culture samples.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: October 3, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
